New study shows inappropriate psychiatric and sedating drugs
prescribed to people with dementia and cognitive impairment
Leqembi (Lecanemab)
New data presented at the 2025 CTAD conference brings good news for families facing early Alzheimer’s.
There are a variety of laboratory-developed tests on the market used to detect blood-based biomarkers associated with Alzheimer’s.
Navigating the U.S.’s federal and state health insurance program, Medicaid, to cover dementia-related long-term care. What you should know
FDA granted full approval to Leqembi (lecanemab), the first therapy proven to slow cognitive decline by clearing out toxic clumps of beta-amyloid called protofibrils as well as larger amyloid plaques from the brain.